In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.
Ondansetron Hydrochloride CR Overview
Ondansetron hydrochloride (RHB-102, Bekinda) is being developed for the treatment of acute gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), and nausea and vomiting associated with chemotherapy and radiation therapy. The drug candidate is administered orally in tablet form. It is a proprietary formulation of 11 daily controlled-release ondansetron. The drug candidate is developed based on CDT (Controlled Delivery Technology) technology. It is a controlled release formulation.
RedHill Biopharmaceutical Overview
RedHill Biopharma (RedHill) is a specialty biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio includes branded prescription medicines, including omeprazole, a combination of amoxicillin and rifabutin; naloxitol; and rifamycins. RedHill is studying its use as a treatment for Crohn’s disease, non-tuberculous mycobacterial (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleansing, cancer and novel coronavirus Product candidates for COVID-19. ). The company has subsidiaries in the United States. RedHill is headquartered in Tel Aviv, Israel.
For complete information on drug-specific PTSR and LoA scores for Ondansetron Hydrochloride CR, purchase the report here.